This presentation was made at the Wind Energy Update O&M conference in Dallas, TX on April 9, 2013. This presentation included an interactive survey of attendees, the results of which have also been uploaded ot SlideShare.
This presentation was made at the Wind Energy Update O&M conference in Dallas, TX on April 9, 2013. This presentation included an interactive survey of attendees, the results of which have also been uploaded ot SlideShare.
This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects.
http://www.researchmoz.us/ocular-pain-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Traveler's Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traveler's Diarrhea and special features on late-stage and discontinued projects.
http://www.researchmoz.us/travelers-diarrhea-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Respiratory Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Depression and special features on late-stage and discontinued projects.
http://www.researchmoz.us/respiratory-depression-pipeline-review-h1-2015-report.html
"Pharmaceutical sciences
and the challenge for a healthcare focused agenda for pharmacists training"
(A interface ensino-profissão no desenvolvimento das Ciências Farmacêuticas)
Rogério Gaspar
(Presidente da SPCF)
21.SET.2016
This report provides comprehensive information on the therapeutic development for H1N1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H1N1 Infection and special features on late-stage and discontinued projects.
http://www.researchmoz.us/h1n1-infection-pipeline-review-h1-2015-report.html
Healthcare Cold Chain Logistics Market | Trends, PricesIMARC Group
The report “Healthcare Cold Chain Logistics Market” prudently analyzes the past, present and future trends in the global Healthcare Cold Chain industry. The Study provides details Helathcare Cold Chain Logistics Market trends such as arket size, trends, segments, geographies, drivers, challenges, logistic requirements, trade, key players, regulations, etc. Link to Report : http://www.imarcgroup.com/healthcare-cold-chain-logistics-market/
This report provides comprehensive information on the therapeutic development for Emphysema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emphysema and special features on late-stage and discontinued projects.
http://www.researchmoz.us/emphysema-pipeline-review-h1-2015-report.html
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period.
This report provides comprehensive information on the therapeutic development for Food Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Food Allergy and special features on late-stage and discontinued projects.
http://www.researchmoz.us/food-allergy-pipeline-review-h1-2015-report.html
A clinical trial is a culmination of the several stages of a drug or medical
device development program that begins with the discovery of a
candidate molecule followed by preclinical toxicology studies in ex vivo, in
vitro, and animal models. Once the candidate molecule shows promising
results in these stages, the next step involves clinical studies on human
subjects. Drug testing in humans is often the most lengthy and expensive
phase of the drug development timeline, and therefore requires extensive
effort and careful execution to maximize the candidate’s chances of
success. In addition to scientific evaluation, clinical studies require
approval by the United States Food and Drug Administration (US FDA),
the regulatory authority in the United States to administer the
experimental drug in humans as well as ship it across state lines. This
approval comes in the form of an Investigational New Drug (IND FDA)
application that is required to be submitted by sponsors, investigators, or
research institutes to the FDA to commence studies on human
participants. The following figure shows the various stages of the drug
development program (Figure 1) marking IND submission on the timeline.
The US Food and Drug Administration (FDA) has established a comprehensive drug
development strategy for US FDA. This strategy is designed to ensure that the drugs
being developed meet the highest standards of safety and efficacy.The IND is a comprehensive document that contains all the information
gained from preclinical and other studies in an organized format. The
FDA reviews and makes the decision to support further clinical studies
from information in the IND that ultimately forms the basis of marketing
approval. INDs can be submitted at any phase during clinical
development to protect the safety and rights of subjects (Phase I) and to
assure adequate scientific evaluation of the drug’s effectiveness and
safety (Phase II and III). The Code of Federal Regulations CFR Title 21.
Part 312 Investigational New Drug Application contains information on
INDs as well as their content and format and should be reviewed
thoroughly by sponsors or investigators prior to submission of an IND
application.
The IND data requirements are important for the development of new drugs and
medical devices. They provide detailed information about the safety and efficacy of a
drug or device before it can be approved for use by the public
Global orphan drug market designation status clinical pipeline trials insigh...KuicK Research
“Global Orphan Drug Market & Clinical Pipeline Insight 2023” Report Highlights:
• Clinical Insight on 800 Orphan Drugs
• Patent Insight, Orphan Designated Indication & Region/Country
• Marketed Orphan Drugs: More Than 300
• Maximum Orphan Designated Drugs in Phase-II: More Than 200
• Global Orphan Drug Designation Criteria
• FDA & EMA Guidelines
This report provides information on the therapeutic development for Penile Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Penile Cancer.
Clinical research : Drug regulatory affairs and Pharmacovigilance.ProfDnyaneshwariJosh
Schedule Y, FDA, Appendices, Post marketing surveillance,Clinical trial,WHO,ICH-GCP, FDA-CFR, Safety,Adverse Drug reaction, Adverse Event(AE), Serious Adverse Event(SAE),Reporting, IND , 3500A form
This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects.
http://www.researchmoz.us/ocular-pain-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Traveler's Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traveler's Diarrhea and special features on late-stage and discontinued projects.
http://www.researchmoz.us/travelers-diarrhea-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Respiratory Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Depression and special features on late-stage and discontinued projects.
http://www.researchmoz.us/respiratory-depression-pipeline-review-h1-2015-report.html
"Pharmaceutical sciences
and the challenge for a healthcare focused agenda for pharmacists training"
(A interface ensino-profissão no desenvolvimento das Ciências Farmacêuticas)
Rogério Gaspar
(Presidente da SPCF)
21.SET.2016
This report provides comprehensive information on the therapeutic development for H1N1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H1N1 Infection and special features on late-stage and discontinued projects.
http://www.researchmoz.us/h1n1-infection-pipeline-review-h1-2015-report.html
Healthcare Cold Chain Logistics Market | Trends, PricesIMARC Group
The report “Healthcare Cold Chain Logistics Market” prudently analyzes the past, present and future trends in the global Healthcare Cold Chain industry. The Study provides details Helathcare Cold Chain Logistics Market trends such as arket size, trends, segments, geographies, drivers, challenges, logistic requirements, trade, key players, regulations, etc. Link to Report : http://www.imarcgroup.com/healthcare-cold-chain-logistics-market/
This report provides comprehensive information on the therapeutic development for Emphysema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emphysema and special features on late-stage and discontinued projects.
http://www.researchmoz.us/emphysema-pipeline-review-h1-2015-report.html
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period.
This report provides comprehensive information on the therapeutic development for Food Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Food Allergy and special features on late-stage and discontinued projects.
http://www.researchmoz.us/food-allergy-pipeline-review-h1-2015-report.html
A clinical trial is a culmination of the several stages of a drug or medical
device development program that begins with the discovery of a
candidate molecule followed by preclinical toxicology studies in ex vivo, in
vitro, and animal models. Once the candidate molecule shows promising
results in these stages, the next step involves clinical studies on human
subjects. Drug testing in humans is often the most lengthy and expensive
phase of the drug development timeline, and therefore requires extensive
effort and careful execution to maximize the candidate’s chances of
success. In addition to scientific evaluation, clinical studies require
approval by the United States Food and Drug Administration (US FDA),
the regulatory authority in the United States to administer the
experimental drug in humans as well as ship it across state lines. This
approval comes in the form of an Investigational New Drug (IND FDA)
application that is required to be submitted by sponsors, investigators, or
research institutes to the FDA to commence studies on human
participants. The following figure shows the various stages of the drug
development program (Figure 1) marking IND submission on the timeline.
The US Food and Drug Administration (FDA) has established a comprehensive drug
development strategy for US FDA. This strategy is designed to ensure that the drugs
being developed meet the highest standards of safety and efficacy.The IND is a comprehensive document that contains all the information
gained from preclinical and other studies in an organized format. The
FDA reviews and makes the decision to support further clinical studies
from information in the IND that ultimately forms the basis of marketing
approval. INDs can be submitted at any phase during clinical
development to protect the safety and rights of subjects (Phase I) and to
assure adequate scientific evaluation of the drug’s effectiveness and
safety (Phase II and III). The Code of Federal Regulations CFR Title 21.
Part 312 Investigational New Drug Application contains information on
INDs as well as their content and format and should be reviewed
thoroughly by sponsors or investigators prior to submission of an IND
application.
The IND data requirements are important for the development of new drugs and
medical devices. They provide detailed information about the safety and efficacy of a
drug or device before it can be approved for use by the public
Global orphan drug market designation status clinical pipeline trials insigh...KuicK Research
“Global Orphan Drug Market & Clinical Pipeline Insight 2023” Report Highlights:
• Clinical Insight on 800 Orphan Drugs
• Patent Insight, Orphan Designated Indication & Region/Country
• Marketed Orphan Drugs: More Than 300
• Maximum Orphan Designated Drugs in Phase-II: More Than 200
• Global Orphan Drug Designation Criteria
• FDA & EMA Guidelines
This report provides information on the therapeutic development for Penile Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Penile Cancer.
Clinical research : Drug regulatory affairs and Pharmacovigilance.ProfDnyaneshwariJosh
Schedule Y, FDA, Appendices, Post marketing surveillance,Clinical trial,WHO,ICH-GCP, FDA-CFR, Safety,Adverse Drug reaction, Adverse Event(AE), Serious Adverse Event(SAE),Reporting, IND , 3500A form
Similar to Research and Markets: Chronic Back Pain Pipeline Insights Report 2015 (20)
Research and Markets: Chronic Back Pain Pipeline Insights Report 2015
1. Research and Markets: Chronic Back Pain Pipeline Insights
Report 2015
DUBLIN--(BUSINESS WIRE)--Research and Markets
(http://www.researchandmarkets.com/research/3q6n79/chronic_back)
has announced the addition of the "Chronic
Back Pain-Pipeline Insights" subscription to their offering.
This Chronic Back Pain-Pipeline Insights, report provides comprehensive
insights about pipeline drugs across this indication. A key objective of
the report is to establish the understanding for all the pipeline drugs
that fall under Chronic Back Pain.
This report provides information on the therapeutic development based on
the Chronic Back Pain dealing with all the pipeline drugs, comparative
analysis at various stages covering Filed, Phase III, Phase II, Phase I,
IND filed, Preclinical, Discovery and unknown stages, therapeutics
assessment by monotherapy and combination products and molecule type
drug information.
The report also covers the companies information involved in the
therapeutic development of the products. It also has highlighted the
discontinued and dormant products.
Key Topics Covered:
2. Chronic Back Pain Overview
Chronic Back Pain Pipeline Therapeutics
Chronic Back Pain Therapeutics under Development by Companies
Chronic Back Pain Late Stage Products (Filed and Phase III)
Comparative Analysis
Chronic Back Pain Mid Clinical Stage Products (Phase II)
Comparative Analysis
Chronic Back Pain Early Clinical Stage Products (Phase I and IND Filed)
Comparative Analysis
Chronic Back Pain Discovery and Pre-Clinical Stage Products
Comparative Analysis
Drug Candidate Profiles
Chronic Back Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Back Pain - Discontinued Products
Chronic Back Pain - Dormant Products
Companies Involved in Therapeutics Development for Chronic Back Pain
Appendix
For more information visit http://www.researchandmarkets.com/research/3q6n79/chronic_back